Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial

Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S-CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in...

Full description

Saved in:

Bibliographic Details
Published in:	Alzheimer's & dementia Vol. 15; no. 11; pp. 1427 - 1436
Main Authors:	Ehrhardt, Stephan, Porsteinsson, Anton P., Munro, Cynthia A., Rosenberg, Paul B., Pollock, Bruce G., Devanand, Davangere P., Mintzer, Jacobo, Rajji, Tarek K., Ismail, Zahinoor, Schneider, Lon S., Baksh, Sheriza N., Drye, Lea T., Avramopoulos, Dimitri, Shade, David M., Lyketsos, Constantine G., Munro, Cynthia, Lee, Hochang, Bienko, Nicholas, Shade, Dave, Jones, Jennifer, Casper, Anne Shanklin, Frangakis, Constantine, Lears, Andy, Baksh, Sheriza, Perin, Jamie, Ryan, Laurie, McKelvy, Alvin D., Rosenberg, Paul, Nowrangi, Milap, Lawrence, Sarah, Schultz, Meghan, Jamil, Nimra, Devanand, D.P., Simon-Pearson, Laura, Pelton Jacobo Mintzer, Gregory, Brawman-Mintzer, Olga, Williams, Arthur, Awkar, Anthony, Keltz, Melanie, Kowalski, Nancy, Lane, Kaitlyn, Martin, Kim, Salem-Spencer, Susan, Widman, Asa, Kumar, Sanjeev, Lourenco, Lillian, Mulsant, Benoit H., Lago, Kyle, Becerra, Maurcio, Dagerman, Karen, Pawluczyk, Sonia, Teodoro, Liberty
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-11-2019
Subjects:	Agitation Alzheimer dementia Escitalopram Neuropsychiatric symptoms Psychosocial intervention Randomized trial Agitation Psychosocial intervention Randomized trial Escitalopram Alzheimer dementia Neuropsychiatric symptoms
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S-CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD. S-CitAD is a NIH-funded, investigator-initiated, randomized, multicenter clinical trial. Participants receive a structured psychosocial intervention (PSI) as standard of care. Participants without sufficient response to PSI are randomized to receive 15 mg escitalopram/day or a matching placebo in addition to PSI. Primary outcome is the Modified Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (mADCS-CGIC). S-CitAD will provide information about a practical, immediately available approach to treating agitation in patients with AD. S-CitAD may become a model of how to evaluate and predict treatment response in patients with AD and agitation as a neuropsychiatric symptom (ClinicalTrials.gov Identifier: NCT03108846).
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 ObjectType-News-4
ISSN:	1552-5260 1552-5279
DOI:	10.1016/j.jalz.2019.06.4946